Cite
MLA Citation
William B. Pearse et al.. “A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.” Leukemia & lymphoma, vol. 62, no. 14, 2021, pp. 3493–3500. http://access.bl.uk/ark:/81055/vdc_100147037218.0x000049